(VIANEWS) – Shares of NYKODE THERAPEUTIC (Oslo Børs Benchmark Index_GI: NYKD.OL) rose by a staggering 20.28% to kr28.70 at 11:36 EST on Wednesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is sliding 0.24% to kr1,225.09, after five sequential sessions in a row of gains. This seems, up to now, a somewhat bearish trend trading session today.
NYKODE THERAPEUTIC’s last close was kr23.86, 42.73% under its 52-week high of kr41.66.
About NYKODE THERAPEUTIC
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of melanoma, lung, head and neck, renal, and bladder cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2007 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, NYKODE THERAPEUTIC has a trailing twelve months EPS of kr-0.75.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.35%.
Yearly Top and Bottom Value
NYKODE THERAPEUTIC’s stock is valued at kr28.70 at 11:36 EST, way under its 52-week high of kr41.66 and way above its 52-week low of kr20.18.
Volatility
NYKODE THERAPEUTIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.11%, a positive 0.25%, and a positive 2.36%.
NYKODE THERAPEUTIC’s highest amplitude of average volatility was 1.56% (last week), 2.64% (last month), and 2.36% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth declined by 89.6%, now sitting on 9.03M for the twelve trailing months.
More news about NYKODE THERAPEUTIC (NYKD.OL).
